That's right, Vin. One of the reason I sold off GenM earlier is when there's news circulating that GenM could be bidding for Thailand. Thailand + NYC expansion is too much though timing wise could be few years apart. Lets not forget that GenM MY segment requires capex for improvement in years to come too. Its a bit far fetching.

Both genting share price below NTA... especially Genting...
Quite attractive..
The price convert to usd around
0.74 usd....
I hope any tycoon can takeover genting at 1.00-1.20usd :-)

The new CEO could be part of a transition phase before another Lim family takes over, Vin. Typical succession planning and could be in 5 to 10 years time assuming he can rise above the occasion. He is now in charge of GenP :)

recession can help too, Jiashen. I saw some news article in the US circulating recently of possible recession and sin stock tends to do well during recession. more than 1000 counters down today :) Looks like I will be able to get the 3.00 batch very soon.

The earliest update for HMTM could be in Apr, Jiashen. The UK marketing authorization approval by UK MHRA and thereafter, NICE to provide guidelines for the use of new medicines/treatments within NHS (for use in hospitals) upon approval by UK MHRA. You can click on the link below for the last update back in Dec'24 by NICE; pending UK MHRA if you will. Scroll down to the bottom of the page in the link. https://www.nice.org.uk/guidance/indevelopment/gid-ta11379

Ok, thanks Eddy. I thought it was just a plan / Taurx's intention to file for marketing authorization with FDA for US market but yet to do so. If they can't get approval from UK MHRA, it is unlikely they will get approval from FDA and EMA.

Higher cost/expenses can lead to lower ebitda, Vin. I am not sure whether did Genting put in actions to strengthens the AML policies (security/systems) before Dec'24 that could add on to the cost/expenses. Higher marketing expenses, a shift between gaming and non-gaming revenue can impact the margins though revenue numbers remain the same and the usual operating cost factors are the few factors that could also contribute to the numbers.

What I did to compute similar conclusion of RWLV performance was to use Genting's US segment number to minus off the US segment number from GenM. That gives me a rough overview of RWLV performance; single digit margins performance. It is double digit close to 20% historically.

Thats right, Vin. I am not sure whether its cyclical or structural as shared few days back. And makes sense to have a CFO there as they may ended up reporting lbitda instead of ebitda if they didnt manage it well. So, US segment is struggling while MY and SG segment is strong. The margins for MY and SG is between 30% to 40%. Within US segment, GenM US segment ebitda margins dipped to mid tens range in Q4 compared to mid to high twenties range.

You are welcome, Vin. The big names of IR operators or Genting's peers are LVS and Wynn. Genting's ebitda margins is comparable to their peers on the surface at 30%+ range; thanks to MY and SG segment. US segment is the undercurrent for Genting that has to be sorted out asap based on Q4'24 performance. Wynn's US segment ebitda margins is close to 30%.

Every new CEO buys back company shares to show confidence in turning the business around. Before an AGM, the CEO must not let the stock price drop because it’s important to show that the market trusts the new leadership. This is especially true when it is the first time non families member leads the company.

For example, in CapitalA’s turnaround, shares were bought by a key investor (Mojo guy) when he announce his plan. The risk is that once this investor has bought enough shares or after about two weeks—when excitement about the new CEO fades—there may be no one left to support the stock price.

I think LKT is managing his private vehicle instead, TN. Back in 2022, KHIL "sold" 20M via TRS deal at 5.17. Basically, KHIL is hedging the upside/downside risk by transferring it to the other party. Fast forward, looks like KHIL did a good job there. Didn't notice any announcement of the termination of the deal so far. And KHIL is buying recently. So, I believed LKT is managing KHIL's interest. No idea what is driving his big purchase recently. Can be the valuation of his company or can be anything :)

You have time to act still if you are eyeing TauRx decision in my personal opinion, TN. Well, you may miss the usual gap up just like any positive news in any other counters but you can still catch up with how much it is worth. Getting the MAA is just the first step in the first market and HMTM has to be in the market within 3 years. There are other markets' MAA to follow suit, FDA for US, EMA for Europe and etc.

Don't panic guys...
在遥远的西方有一个傻仔，昨天issued preference share 酬 21 billion买bitcoin。那个人叫做micheal saylor，公司名字叫microstrategy。他的均价在66k usd per bitcoin，只要跌破这个价格，我们就可以看到death spiral了。这跟上次的luna coin，ftx都有雷同之处，就是摊上这个ponzi scheme。所以如果recession真的发生（昨天delta airline的qr其实已经很明显了），bitcoin会跌到你阿玛都不认得。所以谁敢跟我一起买入两倍leverage 的 etf short爆这个ponzi老呢？

Not so sure about that, 金龙柯基. Wait for the upcoming annual report to check on the shareholdings. There should be some movement from foreign institutions too. I heard moomoo app can check the shareholdings and seems like Blackrock Inc has increased its position. Not sure whether its true or not.

It has been dropping since Aug last year, Vin. Pricing in the RWLV complaints and GenS earnings disruptions. A price gap recently due to the dividend reduction from the recent earnings report. Doubt it will go down further unless dividend is reduced further. GenS is moving up gradually too - probably driven by promising tourism number and reopening of Oceanarium n super luxury all suite hotel in Q3; in 6 months time

Genting Bhd.'s founder Lim family and the CEO's recent share purchases at historically low valuations could signal confidence in the stock, Maybank IB analyst Yin Shao Yang says in a note. Near-term drivers include the potential regulatory approval of its associate TauRx Pharmaceuticals' Alzheimer's combating drug by mid-2025, he says. A favorable resolution to the Nevada Gaming Control Board's investigation into Resorts World Las Vegas's compliance complaint could also improve Genting's earnings visibility, he says. A near-term key risk is its unit losing the pending $600 million lawsuit filed by JV partner RAV Bahamas, Yin says, noting that a decision is expected by June. Maybank raises Genting's rating to buy from hold and maintains its target price at MYR3.98. Shares are 0.3% higher at MYR3.25. (yingxiang.wong@wsj.com)